《瑞信窝轮》药股捱沽赌股反弹留意石药购19353、银河牛57591、金沙牛61833
有报道指，国务院将推进药品集中采购，畅通急需抗癌药进口渠道。医药股捱沽。石药（1093）周三曾急跌逾半成，失守12元关口，是逾4个月的低位。向上阻力留意12元，支持参考11元。看好可考虑石药购19353，行使价13.90元，19年11月到期。或石药牛65204，收回价10.99元，行使价10.29元，19年12月到期。相反看淡可考虑石药沽21108，行使价9.28元，20年3月到期。
中国生物制药（1177）周三更曾跌近7%，险守7元关口。看好可考虑中药购11467，行使价7.67元，19年9月到期。或中药牛69239，收回价5.98元，行使价5.48元，19年12月到期。
连日受压的赌业股反弹，银河娱乐（0027）周三曾升逾4%，一度高见48元以上。向上阻力留意50元水平，支持参考45元。看好可留意银河牛57591，收回价44.88元，行使价44.08元，19年10月到期。相反看淡可留意银河熊62319，收回价51.88元，行使价52.68元，20年1月到期。
另一只赌业股金沙中国（1928），周三亦曾升约4%，但升穿35元後有获利盘出现。看好可留意金沙牛61833，收回价31.88元，行使价31.08元，19年11月到期。永利澳门（1128）亦曾升近6%，一度高见16元以上。看好可留意永利购19461，行使价19.21元，19年12月到期。
(本结构性产品并无抵押品)
《瑞信香港认股证及牛熊证销售主管何启聪》
免责声明：笔者为瑞士信贷(香港)有限公司的代表 ，并身为证监会持牌人，并无持有相关上市公司的任何财务权益。本文内容仅供参考，并不构成要约、建议或促使任何人士提呈买卖或认购任何证券。结构性产品价格可急升或急跌，投资者或会蒙受全盘损失。本产品并无抵押品。如发行人无力偿债或违约，投资者可能无法收回部份或全部应收款项。牛熊证备强制赎回机制而可能被提早终止，届时(i)N类牛熊证投资者将不获发任何金额；而(ii)R类牛熊证之剩余价值可能为零。有关恒生指数或恒生中国企业指数的免责声明，请参阅上市文件。过往表现并不反映将来表现。投资前，投资者应了解风险，并谘询专业顾问及查阅有关上市文件。瑞信之联属公司为结构性产品之流通量提供者，亦可能是唯一报价者。本文任何内容概不构成投资、法律、会计或税务意见、并无声明任何投资或策略适合或符合阁下的个别情况。结构性产品交投量并不是结构性产品表现的指标，投资者不应仅依赖交投量历史高位数据以厘定结构性产品日後的表现。~ 重要声明:
以上资讯由第三方提供，AASTOCKS.com Limited对於任何包含於、经由、连结、下载或从任何与本网站有关服务所获得之资讯、内容或广告，不声明或保证其内容之正确性或可靠性。对於您透过本网站上之广告、资讯或要约而展示、购买或取得之任何产品、资讯资料，本公司亦不负品质保证之责任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
